Queensland Hepatitis C Action Plan 2016–2021...Queensland Hepatitis C Action plan 2016 new...
Transcript of Queensland Hepatitis C Action Plan 2016–2021...Queensland Hepatitis C Action plan 2016 new...
Queensland HealthQH 845 1611
HEPATITIS
HEPATITIS CACTION PLAN 2016–2021
QUEENSLAND
Queensland Hepatitis C Action Plan 2016–2021Published by the State of Queensland (Queensland Health), November 2016
This document is licensed under a Creative Commons Attribution 3.0 Australia licence.
© State of Queensland (Queensland Health) 2016
You are free to copy, communicate and adapt the work, as long as you attribute the State of Queensland (Queensland Health).
For more information contact:Strategic Policy Unit, Department of Health, GPO Box 48, Brisbane QLD 4001
Disclaimer:
The content presented in this publication is distributed by the Queensland Government as an information source only. The State of Queensland makes no statements, representations or warranties about the accuracy, completeness or reliability of any information contained in this publication. The State of Queensland disclaims all responsibility and all liability (including without limitation for liability in negligence) for all expenses, losses, damages and costs you might incur as a result of the information being inaccurate or incomplete in any way, and for any reason reliance was placed on such information.
With the availability of direct acting anti-viral medications that can cure 95 per cent of people with chronic hepatitis C, the Queensland Government is committed to increasing access to hepatitis C treatment and reducing hepatitis C transmission in Queensland.
This action plan acknowledges the current provision of quality hepatitis C prevention, testing and treatment services within Queensland Health, the private sector and community based organisations across Queensland.
The plan complements this ongoing work and will drive a reduction in new hepatitis C infections and increase treatment uptake in Queensland through:
• targeted best practice prevention activities
• increased access to testing for hepatitis C
• increased access to treatment for people diagnosed with chronic hepatitis C.
The success of these efforts depends not on reaching all people but on reaching the right people through effective targeted interventions.
The action plan aligns with the Queensland Sexual Health Strategy 2016–2021, the Queensland Hepatitis B Action Plan 2016–2021 and the Queensland HIV Action Plan 2016–2021 to ensure a comprehensive approach to blood-borne virus prevention and treatment in Queensland. It also aligns with and supports the Fourth National Hepatitis C Strategy 2014–2017 and the Fourth National Aboriginal and Torres Strait Islander Blood-Borne Viruses and Sexually Transmissible Infections Strategy 2014–2017.
The Hon Cameron Dick MP
Minister for Health and Minister for Ambulance Services
Foreword
Hepatitis C causes inflammation of the liver. Chronic infection can result in progressive liver inflammation leading to cirrhosis (scarring of the liver) and cancer.
Hepatitis C virus (HCV) remains the most frequently reported blood borne virus infection in Queensland with 2581 cases notified in 2015.
HCV cases reported in QLD 2015
2581
New treatments listed on the Pharmaceutical Benefits Scheme (PBS) from 1 March 2016 have a cure rate of 95 per cent and are available to everyone over the age of 18 years infected with chronic hepatitis C.
Cure rate for new treatments listed on PBS
95%
New treatments can be prescribed by medical practitioners including general practitioners, who are experienced in the treatment of chronic hepatitis C infection; or in consultation with a gastroenterologist, hepatologist or infectious diseases physician experienced in the treatment of chronic hepatitis C infection.
Hepatitis C at a glance
Out
com
e1.
Impl
emen
t a c
ompr
ehen
sive
ap
proa
ch to
redu
ce h
epat
itis
C
tran
smis
sion
2. In
crea
se v
olun
tary
test
ing
fo
r hep
atiti
s C
3. In
crea
se tr
eatm
ent u
ptak
e by
pe
ople
with
chr
onic
hep
atiti
s C
4.
Incr
ease
aw
aren
ess
of
hepa
titis
C tr
ansm
issi
on,
and
redu
ce s
tigm
a an
d di
scrim
inat
ion
rela
ted
to
hepa
titis
C
Targ
et
popu
latio
nsPe
ople
who
inje
ct d
rugs
, Abo
rigi
nal a
nd
Torr
es S
trai
t Isl
ande
r peo
ple,
cul
tura
lly a
nd
lingu
isti
cally
div
erse
peo
ple,
men
who
hav
e se
x w
ith
men
, peo
ple
in c
usto
dial
set
ting
s an
d yo
ung
peop
le.
Peop
le w
ho in
ject
dru
gs, A
bori
gina
l and
To
rres
Str
ait I
slan
der p
eopl
e, c
ultu
rally
an
d lin
guis
tica
lly d
iver
se p
eopl
e, p
eopl
e in
cu
stod
ial s
etti
ngs,
men
who
hav
e se
x w
ith
men
and
you
ng p
eopl
e.
All p
eopl
e liv
ing
wit
h he
pati
tis C
(inc
ludi
ng
thos
e in
cus
todi
al s
etti
ngs)
, clin
icia
ns
enga
ged
in v
iral
hep
atit
is tr
eatm
ent,
gen
eral
pr
acti
tion
ers
(GPs
), Al
coho
l and
Oth
er
Dru
gs (A
OD
) spe
cial
ists
and
oth
er s
peci
alis
t m
edic
al p
ract
itio
ners
.
Peop
le w
ho in
ject
dru
gs, A
bori
gina
l and
To
rres
Str
ait I
slan
der p
eopl
e, p
eopl
e fr
om c
ultu
rally
and
ling
uist
ical
ly d
iver
se
back
grou
nds,
men
who
hav
e se
x w
ith
men
, pe
ople
in c
usto
dial
set
ting
s an
d G
Ps.
Key
sett
ings
Prim
ary
Hea
lthc
are,
Hos
pita
l and
Hea
lth
Serv
ices
(HHS
s), N
eedl
e an
d Sy
ring
e Pr
ogra
ms
(NSP
s), c
usto
dial
an
d co
mm
unit
y se
ttin
gs
Prim
ary
Hea
lthc
are,
HHS
s, N
SPs,
cu
stod
ial a
nd c
omm
unit
y se
ttin
gsPr
imar
y H
ealt
hcar
e, H
HSs,
NSP
s,
cust
odia
l and
com
mun
ity
sett
ings
NSP
s, c
usto
dial
and
com
mun
ity
sett
ings
Incr
ease
the
prop
ortio
n of
Que
ensl
ande
rs d
iagn
osed
with
chr
onic
hep
atiti
s C
w
ho h
ave
unde
rgon
e tr
eatm
ent t
o 50
per
cen
t by
2021
.GO
AL
HEPA
TITI
S Q
UEE
NSL
AND
ACTI
ON
PLA
N 2
016–
2021
C
Out
com
e1.
Impl
emen
t a c
ompr
ehen
sive
ap
proa
ch to
redu
ce h
epat
itis
C
tran
smis
sion
2. In
crea
se v
olun
tary
test
ing
fo
r hep
atiti
s C
3. In
crea
se tr
eatm
ent u
ptak
e by
pe
ople
with
chr
onic
hep
atiti
s C
4.
Incr
ease
aw
aren
ess
of
hepa
titis
C tr
ansm
issi
on,
and
redu
ce s
tigm
a an
d di
scrim
inat
ion
rela
ted
to
hepa
titis
C
Prio
rity
actio
ns1.
1 En
sure
hep
atiti
s C
prev
entio
n pr
ogra
ms
targ
et p
rior
ity
popu
latio
ns.
1.2
Prom
ote
and
prov
ide
impr
oved
acc
ess
to a
full
rang
e of
ste
rile
inje
ctin
g eq
uipm
ent i
n th
e co
mm
unit
y.
1.3
Supp
ort i
mpr
oved
acc
ess
to O
pioi
d Su
bstit
utio
n Tr
eatm
ent (
OST
) for
pe
ople
who
inje
ct d
rugs
and
are
opi
oid
depe
nden
t, b
oth
in c
omm
unit
y an
d cu
stod
ial s
ettin
gs.
1.4
Prom
ote
and
supp
ort h
arm
redu
ctio
n st
rate
gies
in c
usto
dial
set
tings
.
1.5
Enga
ge w
ith C
omm
unit
y B
ased
O
rgan
isat
ions
(CBO
s) to
incr
ease
co
nsum
er h
epat
itis
C aw
aren
ess,
kn
owle
dge
and
prev
entio
n sk
ills
thro
ugh
peer
edu
catio
n an
d br
ief i
nter
vent
ions
.
1.6
Wor
k w
ith
PHN
s, H
HSs
and
CB
Os
to
pro
mot
e he
pati
tis C
trea
tmen
t as
pre
vent
ion.
1.7
Cont
inue
to c
olle
ct a
nd re
port
on
the
Que
ensl
and
Nee
dle
and
Syri
nge
Prog
ram
Min
imum
Dat
a Se
t and
co
ntin
ue to
par
ticip
ate
in th
e Au
stra
lian
Nee
dle
and
Syri
nge
Prog
ram
Sur
vey.
2.1.
Wor
k w
ith
PHN
s, C
BO
s an
d H
HSs
to
prom
ote
and
incr
ease
acc
ess
to te
stin
g an
d ea
rly
diag
nosi
s of
hep
atit
is C
.
2.2.
Exp
lore
cha
nges
in n
otifi
catio
n cr
iteria
for
prim
ary
hepa
titis
C d
iagn
osis
, foc
usin
g on
the
pres
ence
of c
ircul
atin
g vi
rus
rath
er
than
prio
r exp
osur
e to
the
viru
s.
2.3.
Wor
k w
ith
the
publ
ic la
bora
tory
sec
tor
to m
easu
re th
e ex
tent
of t
esti
ng b
ased
on
the
pres
ence
of c
ircu
lati
ng v
irus
un
dert
aken
follo
win
g he
pati
tis C
an
tibo
dy te
stin
g.
2.4.
Add
ress
bar
rier
s to
test
ing
thro
ugh
targ
eted
mar
keti
ng a
ctiv
itie
s, in
clud
ing
dire
ctio
n to
ser
vice
s, re
duci
ng
stig
ma
in th
e w
ider
com
mun
ity,
an
d cl
inic
ian
enga
gem
ent.
2.5.
Ens
ure
AOD
serv
ices
con
tinue
to p
rom
ote
the
prov
isio
n of
hep
atiti
s C
test
ing.
2.6.
Exa
min
e ho
w h
epat
itis
C n
otifi
cati
on
data
and
pro
cess
es c
an b
e im
prov
ed.
3.1.
Pr
omot
e en
hanc
ed a
cces
s to
hep
atit
is
C as
sess
men
t and
trea
tmen
t, a
nd
supp
ort c
omm
unit
y ba
sed
hepa
titis
C
trea
tmen
t.
3.2.
Co
ntin
ue to
sup
port
fund
ed s
ervi
ce
prov
ider
s to
impr
ove
hepa
titis
C
trea
tmen
t upt
ake
and
adhe
renc
e.
3.3.
Ex
amin
e an
d im
prov
e m
odel
s of
tr
eatm
ent a
nd c
are
to s
uppo
rt
the
trea
tmen
t of h
epat
itis
C in
the
com
mun
ity
by c
onti
nuin
g ex
isti
ng
spec
ialis
t hep
atit
is C
cap
acit
y th
roug
h liv
er a
nd in
fect
ious
dis
ease
s cl
inic
s,
whi
le re
view
ing
cons
ulta
tion
and
in
tegr
ated
pat
hway
s be
twee
n G
P an
d te
rtia
ry c
entr
es.
3.4.
H
HS,
PH
Ns
and
the
CBO
sec
tor t
o w
ork
colla
bora
tive
ly to
opt
imis
e he
pati
tis C
tr
eatm
ent u
ptak
e.
3.5.
Pr
omot
e en
hanc
ed a
cces
s to
hep
atit
is
C tr
eatm
ent i
n AO
D s
ervi
ces
and
cust
odia
l set
ting
s.
4.1.
Co
ntin
ue to
fund
and
sup
port
the
deve
lopm
ent a
nd d
eliv
ery
of ta
rget
ed
stra
tegi
es in
clud
ing:
• so
cial
mar
ketin
g to
edu
cate
and
in
form
the
popu
lati
on a
bout
he
pati
tis C
• in
form
atio
n re
gard
ing
prev
alen
ce
of h
epat
itis
C in
the
com
mun
ity
• in
form
atio
n re
gard
ing
the
natu
re
and
natu
ral h
isto
ry o
f chr
onic
he
pati
tis C
infe
ctio
n•
how
hep
atit
is C
is tr
ansm
itte
d•
how
hep
atit
is C
infe
ctio
n ca
n be
pr
even
ted
• th
e im
port
ance
of t
estin
g fo
r he
pati
tis C
• ne
w tr
eatm
ent o
ptio
ns.
Que
ensl
and
Hep
atiti
s C
Actio
n pl
an 2
016–
2021
Out
com
e1.
Impl
emen
t a c
ompr
ehen
sive
ap
proa
ch to
redu
ce h
epat
itis
C
tran
smis
sion
2. In
crea
se v
olun
tary
test
ing
fo
r hep
atiti
s C
3. In
crea
se tr
eatm
ent u
ptak
e
by p
eopl
e w
ith c
hron
ic
hepa
titis
C
4. In
crea
se a
war
enes
s of
he
patit
is C
tran
smis
sion
, an
d re
duce
stig
ma
and
disc
rimin
atio
n re
late
d to
he
patit
is C
Indi
cato
rsTh
e am
ount
of s
teri
le in
ject
ing
eq
uipm
ent d
istr
ibut
ed
Sour
ce: Q
ueen
slan
d N
eedl
e an
d Sy
ring
e Pr
ogra
m, C
omm
unic
able
Dis
ease
s B
ranc
h,
Dep
artm
ent o
f Hea
lth
Freq
uenc
y: A
nnua
l
The
prop
orti
on o
f peo
ple
who
inje
ct d
rugs
w
ho s
hare
inje
ctin
g eq
uipm
ent
Sour
ce: A
ustr
alia
n N
SP S
urve
y,
Kirb
y In
stit
ute
Freq
uenc
y: A
nnua
l
The
num
ber o
f opi
oid
depe
nden
t pe
ople
rece
ivin
g O
ST
Sour
ce: P
reve
ntio
n D
ivis
ion,
Dep
artm
ent o
f H
ealt
h Fr
eque
ncy:
Ann
ual
Prov
isio
n of
har
m re
duct
ion
init
iati
ves
in
cus
todi
al s
etti
ngs
Sour
ce: Q
ueen
slan
d Co
rrec
tive
Ser
vice
s Fr
eque
ncy:
Ann
ual
The
prop
ortio
n of
men
who
hav
e se
x w
ith m
en
who
are
inje
ctin
g dr
ug u
sers
, rep
ortin
g th
at
they
are
eng
agin
g in
saf
er in
ject
ing
prac
tices
Sour
ce: G
ay C
omm
unit
y Pe
riod
ic S
urve
y,
Cent
re fo
r Soc
ial R
esea
rch
in H
ealt
h Fr
eque
ncy:
Ann
ual
The
prop
orti
on o
f peo
ple
who
cur
rent
ly
inje
ct d
rugs
who
are
test
ed fo
r hep
atit
is C
Sour
ce: A
ustr
alia
n N
SP S
urve
y, K
irby
In
stit
ute
Freq
uenc
y: A
nnua
l
All P
HN
s pr
omot
e th
e pr
ovis
ion
of
hepa
titi
s C
test
ing
and
trea
tmen
t
Sour
ce: S
urve
y of
PH
Ns,
Com
mun
icab
le
Dis
ease
s B
ranc
h, D
epar
tmen
t of H
ealt
h Fr
eque
ncy:
Ann
ual
The
num
ber o
f AO
DS c
lient
s w
ith
a
hist
ory
of in
ject
ing
drug
use
und
erta
king
he
pati
tis
C te
stin
g
Sour
ce: S
urve
y of
AO
D s
ervi
ces,
Co
mm
unic
able
Dis
ease
s B
ranc
h, D
epar
tmen
t of
Hea
lth
Freq
uenc
y: A
nnua
l
The
prop
orti
on o
f peo
ple
diag
nose
d as
hep
atit
is C
ant
ibod
y po
siti
ve w
ho
subs
eque
ntly
hav
e te
stin
g to
det
ect t
he
pres
ence
of c
ircu
lati
ng v
irus
Sour
ce: E
xplo
re c
olle
ctio
n w
ith
Publ
ic
labo
rato
ries
, Que
ensl
and
Hea
lth
Freq
uenc
y: A
nnua
l fro
m 2
018
onw
ards
Deliv
ery
of a
pub
lic h
epat
itis
C
awar
enes
s ca
mpa
ign
Sour
ce: I
nteg
rate
d Co
mm
unic
atio
ns
Bra
nch,
Dep
artm
ent o
f Hea
lth
Freq
uenc
y: O
ne o
ff in
201
6
The
prop
orti
on o
f peo
ple
livin
g w
ith
ch
roni
c he
pati
tis
C re
ceiv
ing
trea
tmen
t
Sour
ce: M
onito
ring
hep
atit
is C
trea
tmen
t up
take
in A
ustr
alia
repo
rt, K
irby
Inst
itut
e Fr
eque
ncy:
Qua
rter
ly
All P
HN
s an
d H
HSs
have
col
labo
rati
ve
arra
ngem
ents
in p
lace
to e
nsur
e ti
mel
y lo
cal
acce
ss to
hep
atit
is C
trea
tmen
t
Sour
ce: S
urve
y of
PH
Ns,
Com
mun
icab
le
Dis
ease
s B
ranc
h, D
epar
tmen
t of H
ealt
h Fr
eque
ncy:
Ann
ual
Prov
isio
n of
chr
onic
hep
atit
is C
trea
tmen
t in
cus
todi
al s
etti
ngs
Sour
ce: S
urve
y of
Pri
son
Hea
lth
Serv
ices
, Co
mm
unic
able
Dis
ease
s B
ranc
h, D
epar
tmen
t of
Hea
lth
Freq
uenc
y: A
nnua
l
Prov
isio
n of
chr
onic
hep
atit
is
trea
tmen
t in
AOD
serv
ices
Sour
ce: S
urve
y of
AO
D s
ervi
ces,
Co
mm
unic
able
Dis
ease
s B
ranc
h,
Dep
artm
ent o
f Hea
lth
Freq
uenc
y: A
nnua
l
Impl
emen
tati
on a
nd e
valu
atio
n of
CBO
bas
ed
chro
nic
hepa
titi
s C
trea
tmen
t pro
ject
s
Sour
ce: F
unde
d se
rvic
e pr
ovid
er re
port
s
Freq
uenc
y: A
nnua
l
Cam
paig
ns in
pla
ce to
rais
e aw
aren
ess
of
hepa
titi
s C
in s
peci
fic s
etti
ngs
or a
mon
g sp
ecifi
c po
pula
tion
s co
nduc
ted
by fu
nded
se
rvic
e pr
ovid
ers
Sour
ce: F
unde
d se
rvic
e pr
ovid
er re
port
s Fr
eque
ncy:
Ann
ual
Que
ensl
and
Hep
atiti
s C
Actio
n pl
an 2
016–
2021
Queensland HealthQH 845 1611
HEPATITIS
HEPATITIS CACTION PLAN 2016–2021
QUEENSLAND
Queensland Hepatitis C Action Plan 2016–2021Published by the State of Queensland (Queensland Health), November 2016
This document is licensed under a Creative Commons Attribution 3.0 Australia licence.
© State of Queensland (Queensland Health) 2016
You are free to copy, communicate and adapt the work, as long as you attribute the State of Queensland (Queensland Health).
For more information contact:Strategic Policy Unit, Department of Health, GPO Box 48, Brisbane QLD 4001
Disclaimer:
The content presented in this publication is distributed by the Queensland Government as an information source only. The State of Queensland makes no statements, representations or warranties about the accuracy, completeness or reliability of any information contained in this publication. The State of Queensland disclaims all responsibility and all liability (including without limitation for liability in negligence) for all expenses, losses, damages and costs you might incur as a result of the information being inaccurate or incomplete in any way, and for any reason reliance was placed on such information.